Share

Excellence in Oncology 2012 to be organized under the auspices of the EORTC

22-25 February 2012, Istanbul, Turkey

Introducing EiO 2012 – The second in a series of annual international conferences in the field of oncology featuring distinguished experts selectively presenting the latest scientific findings and advances in oncology, as these relate to clinical practice.

  • A plethora of distinguished speakers from across the globe
  • A comprehensive annual review of the latest emerging evidence and clinical practices
  • Exclusive structured and unstructured networking opportunities
  • Awards and scientific recognition for the best abstract submissions
  • CME/CPD accreditation provided

Main thematic axes:

  • Prevention & Early Diagnosis of Cancer
  • Diagnosis & Staging of Cancer
  • Treatment of Cancer and Supportive Care of Cancer Patients

Who should attend?

The Conference is addressed primarily to medical oncologists, surgical oncologists and radiation oncologists while it is also of interest to pathologists, radiologists and translational-oriented researchers.

Days to remember:

Last day to register at the “early bird” fee: 17 June 2011
Last day to submit your abstract: 30 September 2011

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023